This page shows the latest TNBC news and features for those working in and with pharma, biotech and healthcare.
It is estimated that around 15% of all breast cancers – with more than 8, 000 cases per years in the UK – are diagnosed as TNBC. ... The trial, funded by MSD, involved 1, 174 patients across 21 countries with previously untreated stage 2 or 3 TNBC.
Effective treatment options are extremely limited in TNBC compared with other breast cancer types and the chance of recurrence and metastases is higher. ... While patients whose tumours express PD-L1 can receive immunotherapies like Merck/MSD’s
Triple-negative breast cancer (TNBC) is an aggressive form of the disease with a high recurrence rate and more commonly diagnosed in in people who are younger than 40, who are ... Keytruda is approved in the same indication in the US as well as for
This is good news for European patients with TNBC, the most aggressive form of the disease, which is more frequently diagnosed in younger and premenopausal women as well as being more ... Effective treatment options are extremely limited for patients
TNBC patients generally experience rapid progression and shorter overall survival compared to other subtypes of breast cancer. ... In July, the FDA gave full approval to Keytruda in both advanced/metastatic and in early-stage TNBC.
This approval is particularly important for the country as so-called ‘triple-negative’ breast cancer (TNBC) is more prevalent in Japan than in the US, with around 15% of patients with ... breast cancer in Japan diagnosed with TNBC.
More from news
Approximately 5 fully matching, plus 36 partially matching documents found.
Trop2 is a transmembrane glycoprotein overexpressed in many epithelial cancer cells, including TNBC.
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior therapies
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...